Michigan Medicine, University of Michigan
Welcome,         Profile    Billing    Logout  
 27 Trials 
33 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Yanik, Gregory
NCT05457556: Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

Recruiting
3
435
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Busilvex, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Echocardiography, EC, Fludarabine, Fluradosa, Haploidentical Hematopoietic Cell Transplantation, Haploidentical Stem Cell Transplantation, HLA-Haploidentical Hematopoietic Cell Transplantation, Stem Cell Transplantation, Haploidentical, Lapine T-Lymphocyte Immune Globulin, Anti-Thymocyte Globulin Rabbit, Antithymocyte Globulin Rabbit, Grafalon, Rabbit Anti-Human Thymocyte Globulin (RATG), Rabbit Anti-Thymocyte Globulin, Rabbit Antithymocyte Globulin, Rabbit ATG, Thymoglobulin, Lumbar Puncture, LP, Spinal Tap, Matched Unrelated Donor Hematopoietic Cell Transplantation, MUD-HCT, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Mycophenolate Mofetil, CellCept, MMF, Myeloablative Conditioning, Myeloablation, Myeloablative, Myeloablative Cytoreduction, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, T-Cell Depletion Therapy, T-Cell Depletion, T-Lymphocyte Depletion Therapy, Tacrolimus, FK 506, FK-506, Fujimycin, Hecoria, Prograf, Protopic, Tacforius, Thiotepa, 1,1',1''-Phosphinothioylidynetrisaziridine, Girostan, N,N', N''-Triethylenethiophosphoramide, Oncotiotepa, STEPA, Tepadina, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Tio-tef, Triethylene Thiophosphoramide, Triethylenethiophosphoramide, Tris(1-aziridinyl)phosphine sulfide, TSPA, WR 45312, Total-Body Irradiation, SCT_TBI, TBI, Total Body Irradiation, Whole Body, Whole Body Irradiation, Whole-Body Irradiation
Children's Oncology Group
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome
12/27
12/27
PAVO, NCT02445222 / 2014-001673-14: CAR-T Long Term Follow Up (LTFU) Study

Recruiting
3
1400
Europe, Canada, Japan, US, RoW
Previously treated CAR-T patients
Novartis Pharmaceuticals, University of Pennsylvania
Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
02/36
02/36
VBP301, NCT05984199: Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Recruiting
1/2
24
US
VCAR33
Vor Biopharma
Leukemia, Myeloid, Acute
12/24
11/26
NCT01590680: Expanded Access Protocol Using 131I-MIBG

Available
N/A
US
I-131 MIBG, I-131 Iobenguane, I-131 meta-iodobenzylguanidine
Jubilant DraxImage Inc.
Neuroblastoma, Pheochromocytoma, Paraganglioma
 
 
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available
N/A
Canada, US, RoW
CTL019, tisagenlecleucel, Kymriah
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
 
 
NCT05866302: Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients

Recruiting
N/A
375
US
University of Michigan Rogel Cancer Center, National Heart, Lung, and Blood Institute (NHLBI)
Chronic Lung Disease, Hematopoietic Cell Transplantation, Graft Versus Host Disease
05/28
05/28
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Recruiting
N/A
99999
US
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
10/41
10/41
Akin, Cem
HARBOR, NCT04910685 / 2020-005173-28: () Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

Recruiting
2/3
463
Europe, US, RoW
Elenestinib, BLU-263, Placebo
Blueprint Medicines Corporation
Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, Smoldering Systemic Mastocytosis
06/28
06/28
Hummel, Scott L

Not yet recruiting
N/A
150
NA
Patient-Centered Actigraphy, Garmin Vivofit II
Weill Medical College of Cornell University, American College of Cardiology, University of Michigan
Frail Elderly
07/16
12/16
Rebalance-HF, NCT04592445: Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF

Recruiting
N/A
80
US
Satera GSN Ablation, Sham Control
Axon Therapies, Inc.
Heart Failure With Preserved Ejection Fraction
04/22
03/23
NCT02997462: Monocyte Phenotypic Changes in Heart Failure

Completed
N/A
60
US
University of Michigan
Heart Failure, Decompensated Heart Failure
06/22
06/22
NCT03170375 / 2006-000303-42: Dietary Prevention of Heart Failure in Hypertensive Metabolic Syndrome

Active, not recruiting
N/A
81
US
Performance of WHEELS-I in promoting DASH/SRD adoption, Phase 2, Effects of a 2-week DASH/SRD intervention vs. control diet on HFpEF functional cardiovascular risk factors, Phase 1
VA Office of Research and Development
Heart Failure
03/24
06/24
NCT06337812: Fiber Supplementation in Heart Failure With Preserved Ejection Fraction (HFpEF)

Recruiting
N/A
30
US
Potato Starch
University of Michigan
Type2diabetes, Heart Failure With Preserved Ejection Fraction
06/25
06/25
NCT05425459: RESPONDER-HF Trial

Recruiting
N/A
750
Europe, Canada, US, RoW
Corvia Atrial Shunt System / IASD System II, Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)
Corvia Medical
Heart Failure, Heart Failure, Diastolic
05/25
03/31
GOURMET-VA, NCT05996328: CSP #2025 - Geriatric OUt-of-hospital Randomized MEal Trial in Heart Failure: Veterans Affairs

Not yet recruiting
N/A
1400
US
Home-delivered meals and short-term dietary counseling, Study -defined standard of care
VA Office of Research and Development
Heart Failure
04/26
09/26
Ellis, Anne K
TEZARS, NCT06189742: Tezepelumab in Allergic Rhinitis and Asthma Study

Recruiting
2
19
Canada
Tezepelumab, TEZSPIRE, tezepelumab-ekko
Dr. Anne Ellis
Asthma With Allergic Rhinitis
04/26
04/26
NCT02745418: The Role of Filaggrin Mutations and Sensitization Pathways in Allergic Rhinitis and Peanut Allergy

Active, not recruiting
N/A
100
Canada
Dr. Anne Ellis
Allergic Rhinitis, Peanut Allergies
11/28
12/28
NCT01590680: Expanded Access Protocol Using 131I-MIBG

Available
N/A
US
I-131 MIBG, I-131 Iobenguane, I-131 meta-iodobenzylguanidine
Jubilant DraxImage Inc.
Neuroblastoma, Pheochromocytoma, Paraganglioma
 
 
NCT01113697: Genetics of the Early and Late Response to Allergen Challenge

Completed
N/A
520
Canada
University of British Columbia, Allergy, Genes and Environment Network (AllerGen), Networks of Centres of Excellence of Canada
Asthma, Allergic Rhinitis
12/23
12/23
Dorsch, Michael P
NCT04755816: A Mobile Application to Promote Self-management and Improve Outcomes in Heart Failure

Terminated
3
62
US
Sodium intervention, Clinical worsening intervention, Educational content
University of Michigan, National Institute on Aging (NIA)
Heart Failure
05/23
05/23
Baptist, Alan
NCT04444895 / 2019-004823-20: A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

Completed
3
73
Europe, Canada, Japan, US
Lanadelumab, DX-2930, SHP643, TAK-743
Shire, Takeda Development Center Americas, Inc.
Angioedema
05/23
05/23
NCT04583007: Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

No Longer Available
N/A
Europe, Canada, US
Lanadelumab 150 mg, TAK-743, SHP643, DX-2930, Lanadelumab 300 mg
Shire, Takeda Development Center Americas, Inc.
Hereditary Angioedema (HAE), Angioedema
 
 
SOAR, NCT05722834: Self-regulation for Older Adults With Asthma Through Remote Education

Completed
N/A
20
US
SOAR intervention
University of Michigan, American Lung Association
Asthma
05/24
05/24
NCT04543461: American Lung Association (ALA) Lung Health Cohort

Recruiting
N/A
4000
US
Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI), American Lung Association, Stanford University
Lung Diseases
09/26
09/26
ATHENA, NCT05445583: Asthma and Technology in Emerging African American Adults

Recruiting
N/A
180
US
Motivational Enhancement System (MES), Supportive Accountability (SA), Text Messaging (SMS), Physical Activity Tracking (PAT)
University of Michigan, National Institute of Nursing Research (NINR)
Asthma
02/25
05/26
RAPID, NCT04287621: Registry of Asthma Patients Initiating DUPIXENT®

Active, not recruiting
N/A
718
Europe, Canada, Japan, US
DUPIXENT®, dupilumab, REGN668, SAR231893
Regeneron Pharmaceuticals, Sanofi
Asthma
07/26
07/26
Kruse, Dawn
STOP360AG, NCT05548283: Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

Recruiting
4
730
Canada, US
Beta-lactam antibiotic, β-lactam, Aminoglycoside, AG
Chris Goss, University of Washington, Medical University of South Carolina, Cystic Fibrosis Foundation
Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
11/26
11/26
NCT06159725: A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

Recruiting
1/2
41
US
CMTX-101, Placebo
Clarametyx Biosciences, Inc.
Persistent Infection, Cystic Fibrosis
02/25
02/25
NCT06052293: Phase 1 Study to Assess Safety and Efficacy of ANG003

Recruiting
1
60
US
ANG003, Dose Level 1, Dose Level 2, Dose Level 3, and Dose Level 4.
Anagram Therapeutics, Inc.
Exocrine Pancreatic Insufficiency
01/24
06/24
CHEC-SC, NCT03350828: CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes

Recruiting
N/A
5000
US
Nicole Hamblett, Cystic Fibrosis Foundation
Cystic Fibrosis
12/24
12/24
NICE-CF, NCT05362344: Colorectal Cancer Screening in Cystic Fibrosis

Recruiting
N/A
350
US
Stool tests, Stool-based Fecal Immunochemical Testing (FIT) test and Stool-based DNA test (Cologuard) test.
University of Washington, the Collaborative Health Studies Coordinating Center, Cystic Fibrosis Foundation
Cystic Fibrosis, Colorectal Cancer, Adenoma
08/24
06/25
MAYFLOWERS, NCT04828382: Prospective Study of Pregnancy in Women With Cystic Fibrosis

Recruiting
N/A
285
US
Amalia Magaret, University of Texas, National Jewish Health, Cystic Fibrosis Foundation
Pregnancy Related, Cystic Fibrosis
12/26
12/26
Knoop, Karol
FLUTE-3, NCT05634746: 24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)

Active, not recruiting
3
218
Canada, US
APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
Ellodi Pharmaceuticals, LP
Eosinophilic Esophagitis
09/24
03/25

Download Options